4.6 Article

Evaluation of four commercial, fully automated SARS-CoV-2 antibody tests suggests a revision of the Siemens SARS-CoV-2 IgG assay

期刊

CLINICAL CHEMISTRY AND LABORATORY MEDICINE
卷 59, 期 6, 页码 1143-1154

出版社

WALTER DE GRUYTER GMBH
DOI: 10.1515/cclm-2020-1758

关键词

COVID-19; orthogonal testing; SARS-CoV-2 antibody; sensitivity; serologic tests; specificity

向作者/读者索取更多资源

This study evaluated the performance characteristics of four automated antibody assays for SARS-CoV-2, all of which showed very high diagnostic specificity. However, the sensitivities of some tests were slightly lower than manufacturer claims in samples collected at least 14 days after disease onset. The Siemens COV2G assay had distinctly lower sensitivity, necessitating a switch to the company's newly filed SARS-CoV-2 IgG assay for follow-up studies. Combination of multiple tests could be considered in clinical practice.
Objectives: Serological tests detect antibodies against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in the ongoing coronavirus disease-19 (COVID-19) pandemic. Independent external clinical validation of performance characteristics is of paramount importance. Methods: Four fully automated assays, Roche Elecsys Anti-SARS-CoV-2, Abbott SARS-CoV-2 IgG, Siemens SARS-CoV-2 total (COV2T) and SARS-CoV-2 IgG (COV2G) were evaluated using 350 pre-pandemic samples and 700 samples from 245 COVID-19 patients (158 hospitalized, 87 outpatients). Results: All tests showed very high diagnostic specificity. Sensitivities in samples collected at least 14 days after disease onset were slightly lower than manufacturers' claims for Roche (93.0%), Abbott (90.8%), and Siemens COV2T (90.3%), and distinctly lower for Siemens COV2G (78.8%). Concordantly negative results were enriched for immunocompromised patients. ROC curve analyses suggest a lowering of the cut-off index for the Siemens COV2G assay. Finally, the combination of two anti-SARS-CoV-2 antibody assays is feasible when considering borderline reactive results. Conclusions: Thorough on-site evaluation of commercially available serologic tests for detection of antibodies against SARS-CoV-2 remains imperative for laboratories. The potentially impaired sensitivity of the Siemens COV2G necessitates a switch to the company's newly filed SARS-CoV-2 IgG assay for follow-up studies. A combination of tests could be considered in clinical practice.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据